Mary Glorieux

Dr. Mary Glorieux

KU Leuven
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RDRuveyda Dok
Ruveyda Dok
MGMary Glorieux
Mary Glorieux
MBMarieke Bamps
Marieke Bamps
Sandra NuytsSandra Nuyts
Sandra Nuyts
Radiotherapy (RT) has a central role in head and neck squamous cell carcinoma (HNSCC) treatment. Targeted therapies modulating DNA damage response (DDR) and more specific cell cycle checkpoints can improve the radiotherapeutic response. Here, we assessed the influence of ataxia-telangiectasia mutated and Rad3-related (ATR) inhibition with the ATR inhibitor AZD6738 on RT response in both human papillomavirus (HPV)-negative and HPV-positive HNSCC. We found that ATR inhibition enhanced RT response in HPV-negative and HPV-positive cell lines independent of HPV status. The radiosensitizing effect of AZD6738 was correlated with checkpoint kinase 1 (CHK1)-mediated abrogation of G2/M-arrest. This resulted in the inhibition of RT-induced DNA repair and in an increase in the percentage of micronucleated cells. We validated the enhanced RT response in HPV-negative and HPV-positive xenograft models. These data demonstrate the potential use of ATR inhibition in combination with RT as a treatment option for both HPV-negative and HPV-positive HNSCC patients.

14 April 2022 in Journal of Applied Poultry Research
Verified
Journal Article
Open access
MGMary Glorieux
Mary Glorieux
LNL.J. Newman
L.J. Newman
YWY. -T. Wang
Y. -T. Wang
PHP. De Herdt
P. De Herdt
JHJ. Hautekeur
J. Hautekeur
JVJ. Verbeke
J. Verbeke